Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 312 entries
Sorted by: Best Match Show Resources per page
Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib.

Journal of clinical pharmacy and therapeutics

Parakh S, Goh M, Andrews MC.
PMID: 26922422
J Clin Pharm Ther. 2016 Jun;41(3):354-356. doi: 10.1111/jcpt.12366. Epub 2016 Feb 28.

WHAT IS KNOWN AND OBJECTIVE: Cutaneous toxicities are commonly seen with BRAF inhibitors, frequently involving painful hyperkeratosis of the feet. We illustrate an unexpected diagnosis of extensive bilateral pedal Kaposi sarcoma masquerading as BRAF inhibitor-related toxicity in a patient...

Cite
Parakh S, Goh M, Andrews MC. Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib. J Clin Pharm Ther. 2016;41(3):354-356doi: 10.1111/jcpt.12366.
Parakh, S., Goh, M., & Andrews, M. C. (2016). Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib. Journal of clinical pharmacy and therapeutics, 41(3), 354-356. https://doi.org/10.1111/jcpt.12366
Parakh, S, et al. "Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib." Journal of clinical pharmacy and therapeutics vol. 41,3 (2016): 354-356. doi: https://doi.org/10.1111/jcpt.12366
Parakh S, Goh M, Andrews MC. Non-HIV-associated Kaposi sarcoma in an immunosuppressed melanoma patient treated with dabrafenib. J Clin Pharm Ther. 2016 Jun;41(3):354-356. doi: 10.1111/jcpt.12366. Epub 2016 Feb 28. PMID: 26922422.
Copy Download .nbib Format: NLM
Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report.

Journal of clinical pharmacy and therapeutics

Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E.
PMID: 27009771
J Clin Pharm Ther. 2016 Jun;41(3):360-361. doi: 10.1111/jcpt.12383. Epub 2016 Mar 23.

WHAT IS KNOWN AND OBJECTIVE: Peripheral vascular adverse events have been reported with ponatinib treatment in chronic myeloid leukaemia (CML) after failure of dasatinib or nilotinib. We here report peripheral arterial occlusive disease (PAOD) in a patient who had...

Cite
Tournaire G, Despas F, Huguet F, et al. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. J Clin Pharm Ther. 2016;41(3):360-361doi: 10.1111/jcpt.12383.
Tournaire, G., Despas, F., Huguet, F., Montastruc, J. L., & Bondon-Guitton, E. (2016). Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. Journal of clinical pharmacy and therapeutics, 41(3), 360-361. https://doi.org/10.1111/jcpt.12383
Tournaire, G, et al. "Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report." Journal of clinical pharmacy and therapeutics vol. 41,3 (2016): 360-361. doi: https://doi.org/10.1111/jcpt.12383
Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib: a case report. J Clin Pharm Ther. 2016 Jun;41(3):360-361. doi: 10.1111/jcpt.12383. Epub 2016 Mar 23. PMID: 27009771.
Copy Download .nbib Format: NLM
Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring.

Journal of clinical pharmacy and therapeutics

Kim T, Jancel T, Kumar P, Freeman AF.
PMID: 26248976
J Clin Pharm Ther. 2015 Oct;40(5):609-611. doi: 10.1111/jcpt.12308. Epub 2015 Aug 06.

WHAT IS KNOWN AND OBJECTIVE: Despite the known significant drug-drug interaction between isavuconazole and tacrolimus, there are no recommendations on dose adjustment when these drugs are given concomitantly. We report on a patient with a mediastinal Aspergillus fumigatus infection...

Cite
Kim T, Jancel T, Kumar P, et al. Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring. J Clin Pharm Ther. 2015;40(5):609-611doi: 10.1111/jcpt.12308.
Kim, T., Jancel, T., Kumar, P., & Freeman, A. F. (2015). Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring. Journal of clinical pharmacy and therapeutics, 40(5), 609-611. https://doi.org/10.1111/jcpt.12308
Kim, T, et al. "Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring." Journal of clinical pharmacy and therapeutics vol. 40,5 (2015): 609-611. doi: https://doi.org/10.1111/jcpt.12308
Kim T, Jancel T, Kumar P, Freeman AF. Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring. J Clin Pharm Ther. 2015 Oct;40(5):609-611. doi: 10.1111/jcpt.12308. Epub 2015 Aug 06. PMID: 26248976; PMCID: PMC5461210.
Copy Download .nbib Format: NLM
Post-operative infection of endoscopic submucosal dissection of early colorectal neoplasms: a case-controlled study using a Japanese database.

Journal of clinical pharmacy and therapeutics

Muro T, Higuchi N, Imamura M, Nakagawa H, Honda M, Nakao K, Izumikawa K, Sasaki H, Kitahara T.
PMID: 26249257
J Clin Pharm Ther. 2015 Oct;40(5):573-577. doi: 10.1111/jcpt.12313. Epub 2015 Aug 06.

WHAT IS KNOWN AND OBJECTIVE: Endoscopic submucosal dissection of early colorectal neoplasms (ESD-ECN) is known to be an operation with risk of contamination, possibly requiring pre-operative antimicrobial prophylaxis for the prevention of post-operative infection. However, an evaluation of the...

Cite
Muro T, Higuchi N, Imamura M, et al. Post-operative infection of endoscopic submucosal dissection of early colorectal neoplasms: a case-controlled study using a Japanese database. J Clin Pharm Ther. 2015;40(5):573-577doi: 10.1111/jcpt.12313.
Muro, T., Higuchi, N., Imamura, M., Nakagawa, H., Honda, M., Nakao, K., Izumikawa, K., Sasaki, H., & Kitahara, T. (2015). Post-operative infection of endoscopic submucosal dissection of early colorectal neoplasms: a case-controlled study using a Japanese database. Journal of clinical pharmacy and therapeutics, 40(5), 573-577. https://doi.org/10.1111/jcpt.12313
Muro, T, et al. "Post-operative infection of endoscopic submucosal dissection of early colorectal neoplasms: a case-controlled study using a Japanese database." Journal of clinical pharmacy and therapeutics vol. 40,5 (2015): 573-577. doi: https://doi.org/10.1111/jcpt.12313
Muro T, Higuchi N, Imamura M, Nakagawa H, Honda M, Nakao K, Izumikawa K, Sasaki H, Kitahara T. Post-operative infection of endoscopic submucosal dissection of early colorectal neoplasms: a case-controlled study using a Japanese database. J Clin Pharm Ther. 2015 Oct;40(5):573-577. doi: 10.1111/jcpt.12313. Epub 2015 Aug 06. PMID: 26249257.
Copy Download .nbib Format: NLM
'On-demand' romiplostim therapy in immune thrombocytopenia.

Journal of clinical pharmacy and therapeutics

Mitrovic M, Elezovic I, Suvajdzic-Vukovic N.
PMID: 26849975
J Clin Pharm Ther. 2016 Jun;41(3):351-353. doi: 10.1111/jcpt.12359. Epub 2016 Feb 06.

WHAT IS KNOWN AND OBJECTIVE: Although thrombopoietin receptor agonists are a second-line treatment for refractory immune thrombocytopenia (ITP), we lack guidelines recommending maintenance modality in patients who achieve complete remission (CR).CASE SUMMARY: We report a patient with refractory ITP...

Cite
Mitrovic M, Elezovic I, Suvajdzic-Vukovic N. 'On-demand' romiplostim therapy in immune thrombocytopenia. J Clin Pharm Ther. 2016;41(3):351-353doi: 10.1111/jcpt.12359.
Mitrovic, M., Elezovic, I., & Suvajdzic-Vukovic, N. (2016). 'On-demand' romiplostim therapy in immune thrombocytopenia. Journal of clinical pharmacy and therapeutics, 41(3), 351-353. https://doi.org/10.1111/jcpt.12359
Mitrovic, M, et al. "'On-demand' romiplostim therapy in immune thrombocytopenia." Journal of clinical pharmacy and therapeutics vol. 41,3 (2016): 351-353. doi: https://doi.org/10.1111/jcpt.12359
Mitrovic M, Elezovic I, Suvajdzic-Vukovic N. 'On-demand' romiplostim therapy in immune thrombocytopenia. J Clin Pharm Ther. 2016 Jun;41(3):351-353. doi: 10.1111/jcpt.12359. Epub 2016 Feb 06. PMID: 26849975.
Copy Download .nbib Format: NLM
Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma.

Journal of clinical pharmacy and therapeutics

Tan M, Quintal L.
PMID: 26123624
J Clin Pharm Ther. 2015 Oct;40(5):504-507. doi: 10.1111/jcpt.12304. Epub 2015 Jun 29.

WHAT IS KNOWN AND OBJECTIVE: To review the pharmacology, efficacy, safety, formulary and economic considerations of pembrolizumab, a novel, first-in-class, anti-PD-1 monoclonal antibody for treatment of advanced melanoma.METHODS: A literature search was conducted using PubMed (July 2013-December 2014) with...

Cite
Tan M, Quintal L. Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. J Clin Pharm Ther. 2015;40(5):504-507doi: 10.1111/jcpt.12304.
Tan, M., & Quintal, L. (2015). Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. Journal of clinical pharmacy and therapeutics, 40(5), 504-507. https://doi.org/10.1111/jcpt.12304
Tan, M, and Quintal, L. "Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma." Journal of clinical pharmacy and therapeutics vol. 40,5 (2015): 504-507. doi: https://doi.org/10.1111/jcpt.12304
Tan M, Quintal L. Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. J Clin Pharm Ther. 2015 Oct;40(5):504-507. doi: 10.1111/jcpt.12304. Epub 2015 Jun 29. PMID: 26123624.
Copy Download .nbib Format: NLM
Estimating risk from underpowered, but statistically significant, studies: was APPROVe on TARGET?.

Journal of clinical pharmacy and therapeutics

La Caze A, Duffull S.
PMID: 22023341
J Clin Pharm Ther. 2011 Dec;36(6):637-41. doi: 10.1111/j.1365-2710.2010.01222.x. Epub 2010 Dec 12.

WHAT IS KNOWN AND OBJECTIVE: The importance of statistical power is widely recognized from a pre-trial perspective, and when interpreting results that are not statistically significant. It is less well recognized that poor power can lead to inflated estimates...

Cite
La Caze A, Duffull S. Estimating risk from underpowered, but statistically significant, studies: was APPROVe on TARGET?. J Clin Pharm Ther. 2010;36(6):637-41doi: 10.1111/j.1365-2710.2010.01222.x.
La Caze, A., & Duffull, S. (2011). Estimating risk from underpowered, but statistically significant, studies: was APPROVe on TARGET?. Journal of clinical pharmacy and therapeutics, 36(6), 637-41. https://doi.org/10.1111/j.1365-2710.2010.01222.x
La Caze, A, and Duffull, S. "Estimating risk from underpowered, but statistically significant, studies: was APPROVe on TARGET?." Journal of clinical pharmacy and therapeutics vol. 36,6 (2011): 637-41. doi: https://doi.org/10.1111/j.1365-2710.2010.01222.x
La Caze A, Duffull S. Estimating risk from underpowered, but statistically significant, studies: was APPROVe on TARGET?. J Clin Pharm Ther. 2011 Dec;36(6):637-41. doi: 10.1111/j.1365-2710.2010.01222.x. Epub 2010 Dec 12. PMID: 22023341.
Copy Download .nbib Format: NLM
Reducing overestimation of the treatment effect by interim analysis when designing clinical trials.

Journal of clinical pharmacy and therapeutics

Shimura M.
PMID: 30414384
J Clin Pharm Ther. 2019 Apr;44(2):243-248. doi: 10.1111/jcpt.12777. Epub 2018 Nov 10.

WHAT IS KNOWN AND OBJECTIVE: Several researchers in the statistical and medical communities have noted the overestimation of the treatment effect when a trial is stopped early in the interim analysis for efficacy; however, methods to reduce this overestimation...

Cite
Shimura M. Reducing overestimation of the treatment effect by interim analysis when designing clinical trials. J Clin Pharm Ther. 2018;44(2):243-248doi: 10.1111/jcpt.12777.
Shimura, M. (2019). Reducing overestimation of the treatment effect by interim analysis when designing clinical trials. Journal of clinical pharmacy and therapeutics, 44(2), 243-248. https://doi.org/10.1111/jcpt.12777
Shimura, Masashi. "Reducing overestimation of the treatment effect by interim analysis when designing clinical trials." Journal of clinical pharmacy and therapeutics vol. 44,2 (2019): 243-248. doi: https://doi.org/10.1111/jcpt.12777
Shimura M. Reducing overestimation of the treatment effect by interim analysis when designing clinical trials. J Clin Pharm Ther. 2019 Apr;44(2):243-248. doi: 10.1111/jcpt.12777. Epub 2018 Nov 10. PMID: 30414384.
Copy Download .nbib Format: NLM
Retraction.

Journal of clinical pharmacy and therapeutics

[No authors listed]
PMID: 29499095
J Clin Pharm Ther. 2018 Apr;43(2):312. doi: 10.1111/jcpt.12662. Epub 2018 Jan 13.

'Influence of genetic variants of IDH1, IDH2, TET2 and DNMT3A on cytarabine cytotoxicity in different populations' by Y. Wang & J. K. LambaREFERENCE: 1. Wang Y, Lamba JK. Influence of genetic variants of IDH1, IDH2, TET2 and DNMT3A on...

Cite
Retraction. J Clin Pharm Ther. 2018;43(2):312doi: 10.1111/jcpt.12662.
(2018). Retraction. Journal of clinical pharmacy and therapeutics, 43(2), 312. https://doi.org/10.1111/jcpt.12662
"Retraction." Journal of clinical pharmacy and therapeutics vol. 43,2 (2018): 312. doi: https://doi.org/10.1111/jcpt.12662
Retraction. J Clin Pharm Ther. 2018 Apr;43(2):312. doi: 10.1111/jcpt.12662. Epub 2018 Jan 13. PMID: 29499095.
Copy Download .nbib Format: NLM
Adherence to controller asthma medications: 6-month prevalence across a US community pharmacy chain.

Journal of clinical pharmacy and therapeutics

Feehan M, Ranker L, Durante R, Cooper DK, Jones GJ, Young DC, Munger MA.
PMID: 26291693
J Clin Pharm Ther. 2015 Oct;40(5):590-593. doi: 10.1111/jcpt.12316. Epub 2015 Aug 20.

WHAT IS KNOWN AND OBJECTIVE: Non-adherence to controller asthma medications is an important public health problem. It is estimated to occur in 30-70% of individuals and is a significant risk factor for asthma morbidity and mortality. The aim of...

Cite
Feehan M, Ranker L, Durante R, et al. Adherence to controller asthma medications: 6-month prevalence across a US community pharmacy chain. J Clin Pharm Ther. 2015;40(5):590-593doi: 10.1111/jcpt.12316.
Feehan, M., Ranker, L., Durante, R., Cooper, D. K., Jones, G. J., Young, D. C., & Munger, M. A. (2015). Adherence to controller asthma medications: 6-month prevalence across a US community pharmacy chain. Journal of clinical pharmacy and therapeutics, 40(5), 590-593. https://doi.org/10.1111/jcpt.12316
Feehan, M, et al. "Adherence to controller asthma medications: 6-month prevalence across a US community pharmacy chain." Journal of clinical pharmacy and therapeutics vol. 40,5 (2015): 590-593. doi: https://doi.org/10.1111/jcpt.12316
Feehan M, Ranker L, Durante R, Cooper DK, Jones GJ, Young DC, Munger MA. Adherence to controller asthma medications: 6-month prevalence across a US community pharmacy chain. J Clin Pharm Ther. 2015 Oct;40(5):590-593. doi: 10.1111/jcpt.12316. Epub 2015 Aug 20. PMID: 26291693.
Copy Download .nbib Format: NLM
Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis.

Journal of clinical pharmacy and therapeutics

Gong H, Su Y, Zhao L, Ma L, Zhang L, Hou L, Li T, Niu S, Zhang H, Li C, Jin X, Ge L, Leng G, Liu Y.
PMID: 34796971
J Clin Pharm Ther. 2021 Nov 18; doi: 10.1111/jcpt.13570. Epub 2021 Nov 18.

WHAT IS KNOWN AND OBJECTIVE: An increasing number of targeted drugs have been used to treat advanced or metastatic gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, the optimal treatment efficacy of these drugs is still controversial. The...

Cite
Gong H, Su Y, Zhao L, et al. Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis. J Clin Pharm Ther. 2021;doi: 10.1111/jcpt.13570.
Gong, H., Su, Y., Zhao, L., Ma, L., Zhang, L., Hou, L., Li, T., Niu, S., Zhang, H., Li, C., Jin, X., Ge, L., Leng, G., & Liu, Y. (2021). Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis. Journal of clinical pharmacy and therapeutics, . https://doi.org/10.1111/jcpt.13570
Gong, Hongxia, et al. "Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis." Journal of clinical pharmacy and therapeutics vol. (2021). doi: https://doi.org/10.1111/jcpt.13570
Gong H, Su Y, Zhao L, Ma L, Zhang L, Hou L, Li T, Niu S, Zhang H, Li C, Jin X, Ge L, Leng G, Liu Y. Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis. J Clin Pharm Ther. 2021 Nov 18; doi: 10.1111/jcpt.13570. Epub 2021 Nov 18. PMID: 34796971.
Copy Download .nbib Format: NLM
Clinical outcomes of pharmaceutical care intervention in HIV positive patients with hypertension: A randomized controlled study.

Journal of clinical pharmacy and therapeutics

Jackson IL, Ukwe CV.
PMID: 33666264
J Clin Pharm Ther. 2021 Aug;46(4):1083-1094. doi: 10.1111/jcpt.13400. Epub 2021 Mar 05.

WHAT IS KNOWN AND OBJECTIVE: Pharmaceutical care (PC) has been shown to improve clinical outcomes in hypertensive patients as well as in people living with HIV (PLWHV). The objective of this study was to evaluate the impact of PC...

Cite
Jackson IL, Ukwe CV. Clinical outcomes of pharmaceutical care intervention in HIV positive patients with hypertension: A randomized controlled study. J Clin Pharm Ther. 2021;46(4):1083-1094doi: 10.1111/jcpt.13400.
Jackson, I. L., & Ukwe, C. V. (2021). Clinical outcomes of pharmaceutical care intervention in HIV positive patients with hypertension: A randomized controlled study. Journal of clinical pharmacy and therapeutics, 46(4), 1083-1094. https://doi.org/10.1111/jcpt.13400
Jackson, Idongesit L, and Ukwe, Chinwe V. "Clinical outcomes of pharmaceutical care intervention in HIV positive patients with hypertension: A randomized controlled study." Journal of clinical pharmacy and therapeutics vol. 46,4 (2021): 1083-1094. doi: https://doi.org/10.1111/jcpt.13400
Jackson IL, Ukwe CV. Clinical outcomes of pharmaceutical care intervention in HIV positive patients with hypertension: A randomized controlled study. J Clin Pharm Ther. 2021 Aug;46(4):1083-1094. doi: 10.1111/jcpt.13400. Epub 2021 Mar 05. PMID: 33666264.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 312 entries